Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLPT 
Clearpoint Neuro Inc (CLPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29
1 Year Target Price $29
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.27% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 430.16M USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 2 | Beta 0.98 | 52 Weeks Range 9.76 - 30.10 | Updated Date 11/29/2025 |
52 Weeks Range 9.76 - 30.10 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.18 | Actual -0.21 |
Profitability
Profit Margin -67.4% | Operating Margin (TTM) -59.54% |
Management Effectiveness
Return on Assets (TTM) -28.3% | Return on Equity (TTM) -103.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 427684533 | Price to Sales(TTM) 12.53 |
Enterprise Value 427684533 | Price to Sales(TTM) 12.53 | ||
Enterprise Value to Revenue 12.46 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 29748308 | Shares Floating 25999368 |
Shares Outstanding 29748308 | Shares Floating 25999368 | ||
Percent Insiders 7.83 | Percent Institutions 39.98 |
Upturn AI SWOT
Clearpoint Neuro Inc
Company Overview
History and Background
Clearpoint Neuro, Inc. (formerly MRI Interventions, Inc.) was founded in 1998. It focuses on developing and commercializing platforms for targeted drug delivery and minimally invasive surgical procedures in the brain. The company has evolved from focusing primarily on MRI-guided neurosurgery to a broader platform approach for delivering therapies directly to the brain.
Core Business Areas
- Neuro Navigation: Development and commercialization of the ClearPoint System, a neuro-navigation platform enabling real-time MRI-guided procedures for drug delivery, gene therapy, and laser ablation.
- Biologics and Drug Delivery: Partnering with pharmaceutical and biotech companies to utilize the ClearPoint System for delivering therapeutics, including gene and cell therapies, directly to the brain.
- Neuro-Monitoring: Development of neuro-monitoring products to assess the safety and efficacy of therapy delivery.
Leadership and Structure
Joe Burnett is the President and CEO. The company has a board of directors overseeing its strategic direction. The organizational structure is functional, with departments dedicated to research and development, clinical affairs, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- ClearPoint System: A neuro-navigation platform allowing for real-time MRI-guided procedures. Market share is difficult to ascertain precisely as it's a niche area, but the company claims to be a leader in MRI-guided drug delivery in the brain. Competitors include companies developing alternative delivery methods like convection-enhanced delivery (CED) and other surgical navigation systems, but few have the same level of MRI integration.
- SmartFlow Cannula: A micro-catheter system used with the ClearPoint System for targeted drug delivery. There is no public market share information available, however, it is one of the crucial components that help to utilize the Clearpoint system. Competitors include companies developing alternative cannula systems for drug delivery, such as those designed for CED.
Market Dynamics
Industry Overview
The industry is characterized by a growing demand for minimally invasive neurosurgical procedures and targeted drug delivery to the brain, driven by advancements in gene therapy, cell therapy, and biologics.
Positioning
Clearpoint Neuro is positioned as a leader in MRI-guided neuro-navigation and targeted drug delivery. Its competitive advantage lies in its integrated platform that combines real-time imaging with precise delivery capabilities.
Total Addressable Market (TAM)
The TAM for targeted drug delivery and minimally invasive neurosurgery is substantial and growing, potentially reaching billions of dollars. Clearpoint Neuro is positioned to capture a significant share of this market by offering a unique and effective solution.
Upturn SWOT Analysis
Strengths
- Proprietary ClearPoint System platform
- Strong partnerships with pharmaceutical and biotech companies
- Experienced leadership team
- Growing number of clinical applications
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on partnerships for revenue generation
- Slow adoption rate due to high cost of the ClearPoint System
- Small number of products available
Opportunities
- Expanding into new therapeutic areas, such as Parkinson's disease and Alzheimer's disease
- Developing new neuro-monitoring products
- Increasing adoption of the ClearPoint System in academic medical centers
- Expanding into international markets
Threats
- Competition from larger medical device companies
- Regulatory hurdles for new products and therapies
- Reimbursement challenges from payers
- Technological advancements that could render the ClearPoint System obsolete
Competitors and Market Share
Key Competitors
- MEDT
- STJ
- BSX
Competitive Landscape
Clearpoint Neuro's competitive advantage lies in its proprietary ClearPoint System platform and its partnerships with pharmaceutical and biotech companies. However, it faces competition from larger medical device companies with greater financial resources and broader product portfolios.
Major Acquisitions
Impedance Monitoring Technology
- Year: 2021
- Acquisition Price (USD millions): 0.5
- Strategic Rationale: Expanded neuromonitoring capabilities to improve therapy delivery within the ClearPoint System. This enhanced real-time feedback during neurosurgical procedures.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by periods of rapid revenue growth followed by slower growth or declines.
Future Projections: Future growth is projected to be driven by increasing adoption of the ClearPoint System in new therapeutic areas and geographic markets. Analyst estimates vary, but most project continued revenue growth.
Recent Initiatives: Recent strategic initiatives include partnering with new pharmaceutical and biotech companies, developing new neuro-monitoring products, and expanding into international markets.
Summary
Clearpoint Neuro is a promising company in the neurosurgical navigation and drug delivery space. The companyu2019s ClearPoint System has several competitive advantages due to it's partnerships. The company is an early stage company, so the risk will be high and growth has been erratic. It needs to scale and become profitable to have more financial stability in the future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be complete or accurate. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearpoint Neuro Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2020-02-12 | President, CEO & Director Mr. Joseph Michael Burnett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 115 | Website https://www.clearpointneuro.com |
Full time employees 115 | Website https://www.clearpointneuro.com | ||
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.